Remnant gastric cancer: a neglected group with high potential for immunotherapy

Purpose The importance of targeted therapy and interest in the study of predictive markers in gastric cancer (GC) have increased in recent years with the use of anti-HER2 therapy and immunotherapy with anti-PD1/PD-L1 for microsatellite instability (MSI) and PD-L1 + tumors. However, the behavior of r...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2020-12, Vol.146 (12), p.3373-3383
Main Authors: Ramos, Marcus Fernando Kodama Pertille, Pereira, Marina Alessandra, de Castria, Tiago Biachi, Ribeiro, Renan Ribeiro e, Cardili, Leonardo, de Mello, Evandro Sobroza, Zilberstein, Bruno, Ribeiro-Júnior, Ulysses, Cecconello, Ivan
Format: Article
Language:English
Subjects:
Adult
B7-H1 Antigen - antagonists & inhibitors
B7-H1 Antigen - immunology
Biomarkers, Tumor - genetics
Cancer Research
ErbB-2 protein
Female
Gastrectomy
Gastric cancer
Hematology
Humans
Immunohistochemistry
Immunotherapy
Immunotherapy - methods
Internal Medicine
Kaplan-Meier Estimate
Lymph Node Excision - methods
Lymph nodes
Male
Medical prognosis
Medicine
Medicine & Public Health
Microsatellite Instability
Middle Aged
Oncology
Original Article – Clinical Oncology
PD-1 protein
PD-L1 protein
Prognosis
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
Receptor, ErbB-2 - immunology
Retinal ganglion cells
Stomach Neoplasms - immunology
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Stomach Neoplasms - therapy
Survival
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The importance of targeted therapy and interest in the study of predictive markers in gastric cancer (GC) have increased in recent years with the use of anti-HER2 therapy and immunotherapy with anti-PD1/PD-L1 for microsatellite instability (MSI) and PD-L1 + tumors. However, the behavior of remnant GC (RGC) in this scenario is poorly reported. Thus, this study aims to evaluate the clinicopathological characteristics and prognosis of RGC and its association with the expression of current markers for targeted therapy. Methods All RGC resections performed in a single center from 2009 to 2019 were retrospectively reviewed. As a comparison group, 53 primary proximal GC (PGC) who underwent total D2-gastrectomy were selected. HER2, MSI status and PD-L1 expression were analyzed by immunohistochemistry. Combined Positive Score (CPS) was used to determine PD-L1 positivity. Results A total of 40 RGC were included. RGC patients were older ( p  = 0.001), had lower BMI ( p  = 0.001) and number of resected lymph nodes ( p  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-020-03322-7